BenzingaOctober 15, 2026 at 1:23 PM NY12 Days Ago
UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978
UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
